SIRION Biotech is Europe’s leading commercial supplier of viral vector technologies, offering the most comprehensive portfolio of custom viral vectors at shortest response times and with the most professional and personal project management services. SIRION vectors are being used for gene function research, preclinical target validation, gene therapy & vaccine development. Sirion technologies are currently licensed for several major clinical trials (phases I and III).
The company began business in 2007 and since then has been changing the paradigm of viral vector supplies. Specifically,
– all common vector types are available within a matter of weeks – adenovirus, adeno-associated virus (AAV) and lentivirus
– a full range of virus related services at your fingertips spanning from
- Transduction optimization
- Cell modelling
- at highest titers and in quantities required for preclinical, clinical and animal testing.
The company is easily accessible with presence in Munich, Tokyo, South Korea and Tel Aviv. Commercial arrangements range from fee-for-service over IP-generating collaborations all the way to milestone & licensing arrangements. The business model proves successful: an annual 70% growth since 2007 and experienced in more than 300 projects for both the academic and industry sector.
The company is privately held and has over the years raised funds from 8 investors both private and government. In order to support further growth and to benefit from technology development in this exciting industry, the company welcomes new investors. Please contact Management for further information about the company and its future plans.